Sandbox Reserved 712
From Proteopedia
| |||||||||
| 3ggu, resolution 1.80Å () | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ligands: | |||||||||
| Gene: | Gag-Pol, pol (Viruses) | ||||||||
| Activity: | HIV-1 retropepsin, with EC number 3.4.23.16 | ||||||||
| Related: | 3ggt | ||||||||
| |||||||||
| |||||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||
Contents |
Description
3ggu is a drug resistant HIV protease. Shown is a patient's variant in complex with darunavir.
HIV proteases (PR) are essential for the functioning of the retrovirus that causes AIDS. HIV needs active proteases to process gag & gap - polymerase polyprotein precursors into mature structural proteins and replicative enzymes. HIV proteases contain a highly conserved region Asp - Thr - Gly (Asp25, Thr26 and Gly27), with the aspartic residue beeing the active site in the aspartyl protease.[1]
Because of its importance for the life-cycle of the retrovirus, HIV-PR are the major target for anti-HIV treatment. HIV protease inhibitors are the most potent agens used in anti-HIV treatment. However it occurs that HIV-PR develop a resistance to the inhibitor. [2]
3ggu (also PRDRV5) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. [3]
Activity
|
Darunavir as a PI
Prevalence of daruanvir resistance mutations in a large clinical database
Enzymatic analysis of recombinant PRs
Samples PRdrv1 to PRdrv6 have been cloned and expressed in E. coli, purified and characterized in vitro by monitoring cleavage of a chromogenic peptide substrate in the presence and absence of specific PIs.
Despite there were many mutations the kcat values still were between 30 and 50% of the wild-type value. In contrast the Km values of the mutants were (mostly) four- to eightfold higher than the wild-type PR. [3]
(Complete Table: Enzyme characteristics of PR variants analyzed in this study)
Inhibition constants were determined by kinetic analysis using a chromogenic peptide substrate and the appropriate inhibitor. PRdrv5 - which only had a specific activity of 5% of the wild-type value - also shows a smaller difference in ki value for darunavir, even if it contains 20 mutations.(Complete Table: Ki values for the inhibitors of PR mutants) Among those 20, some are responsible for cross-resistance to other PIs (L10I, L33F, M46L, I54V, A71V, V82T, I84V, L89V and L90M). The three amprenavir- and darunavir-associated mutations (V32I, I47V and I54L/M) don't exist in PRdrv5 (but in PRdrv1 and PRdrv6. [3]
Vitality describes the relative ability of a given PR species to hydrolyze its substrate in the presence of an inhibitor. The higer the vitality value the greater the advantage given to that PR species
Enzymatic analysis of recombinant PRs
Samples PRdrv1 to PRdrv6 have been cloned and expressed in E. coli, purified and characterized in vitro by monitoring cleavage of a chromogenic peptide substrate in the presence and absence of specific PIs.
Despite there were many mutations the kcat values still were between 30 and 50% of the wild-type value. In contrast the Km values of the mutants were (mostly) four- to eightfold higher than the wild-type PR. [3]
(Complete Table: Enzyme characteristics of PR variants analyzed in this study)
Inhibition constants were determined by kinetic analysis using a chromogenic peptide substrate and the appropriate inhibitor. PRdrv5 - which only had a specific activity of 5% of the wild-type value - also shows a smaller difference in ki value for darunavir, even if it contains 20 mutations.(Complete Table: Ki values for the inhibitors of PR mutants) Among those 20, some are responsible for cross-resistance to other PIs (L10I, L33F, M46L, I54V, A71V, V82T, I84V, L89V and L90M). [3]
X-ray strucure analysis of PRdrv1 and PRdrv5
Structure
Applications
External Resources
References
- ↑ Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90. PMID:3290901
- ↑ Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 2003 Feb;47(2):759-69. PMID:12543689
- ↑ 3.0 3.1 3.2 3.3 3.4 Saskova KG, Kozisek M, Rezacova P, Brynda J, Yashina T, Kagan RM, Konvalinka J. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J Virol. 2009 Sep;83(17):8810-8. Epub 2009 Jun 17. PMID:19535439 doi:10.1128/JVI.00451-09
Contributors
Julia Baaske, Angelika Wackerl
